Physician profile
Brianda Ulloa
NPI 1770188468
$4,733.58
in general payments reported to CMS, 2019-2025
30 companies · $303 in 2025
The $303 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $869 · 2022: $2,167 · 2023: $1,395 · 2025: $303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,666 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,665.55 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $733.65 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Novo Nordisk INC | $681.13 | 2021-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $402.49 | 2022-2023 | Farxiga |
| Lilly USA, LLC | $399.35 | 2021-2023 | Mounjaro, Jardiance |
| Dexcom, INC. | $276.29 | 2021-2023 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $258.32 | 2022-2023 | |
| Ibsa Pharma INC. | $206.20 | 2022-2023 | Tirosint, Licart |
| Corcept Therapeutics | $190.49 | 2021-2025 | Korlym |
| Medtronic, INC. | $155.83 | 2021-2025 | Minimed 780g, Minimed 770g |
| Kyowa Kirin, INC. | $153.37 | 2023 | Crysvita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.52 | 2021-2025 | Jardiance |
| Mannkind Corporation | $125.59 | 2021-2023 | Afrezza |
| Amgen INC. | $114.32 | 2021-2025 | Evenity |
| Insulet Corporation | $108.84 | 2021-2023 | Omnipod |
| Abbvie INC. | $91.41 | 2021-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $85.06 | 2021-2023 | |
| Alexion Pharmaceuticals, INC. | $77.79 | 2021-2022 | |
| Radius Health, INC. | $76.62 | 2022-2023 | Tymlos |
| Horizon Therapeutics Plc | $72.49 | 2022 | |
| Xeris Pharmaceuticals, INC. | $52.90 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $47.29 | 2021-2023 | Steglatro, Belsomra |
| Recordati_rare_diseases_inc. | $44.03 | 2021 | |
| Bigfoot Biomedical INC | $36.91 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $36.46 | 2021-2022 | |
| Pfizer INC. | $33.01 | 2022-2023 | |
| Esperion Therapeutics, INC. | $31.57 | 2021 | |
| Ascendis Pharma Endocrinology INC | $29.50 | 2025 | Yorvipath |
| Embecta Corp. | $24.16 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Alvogen INC | $22.08 | 2022 | |
| Tandem Diabetes Care, INC. | $18.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brianda Ulloa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.